Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition

Yujie Tang, Sharareh Gholamin, Simone Schubert, Minde I. Willardson, Alex Lee, Pratiti Bandopadhayay, Guillame Bergthold, Sabran Masoud, Brian Nguyen, Nujsaubnusi Vue, Brianna Balansay, Furong Yu, Sekyung Oh, Pamelyn Woo, Spenser Chen, Anitha Ponnuswami, Michelle Monje, Scott X. Atwood, Ramon J. Whitson, Siddhartha Mitra & 9 others Samuel H. Cheshier, Jun Qi, Rameen Beroukhim, Jean Y. Tang, Rob Wechsler-Reya, Anthony E. Oro, Brian A. Link, James E. Bradner, Yoon-Jae Cho

Research output: Contribution to journalArticle

148 Citations (Scopus)

Abstract

Hedgehog signaling drives oncogenesis in several cancers, and strategies targeting this pathway have been developed, most notably through inhibition of Smoothened (SMO). However, resistance to Smoothened inhibitors occurs by genetic changes of Smoothened or other downstream Hedgehog components. Here we overcome these resistance mechanisms by modulating GLI transcription through inhibition of bromo and extra C-terminal (BET) bromodomain proteins. We show that BRD4 and other BET bromodomain proteins regulate GLI transcription downstream of SMO and suppressor of fused (SUFU), and chromatin immunoprecipitation studies reveal that BRD4 directly occupies GLI1 and GLI2 promoters, with a substantial decrease in engagement of these sites after treatment with JQ1, a small-molecule inhibitor targeting BRD4. Globally, genes associated with medulloblastoma- specific GLI1 binding sites are downregulated in response to JQ1 treatment, supporting direct regulation of GLI activity by BRD4. Notably, patient- and GEMM (genetically engineered mouse model)-derived Hedgehog-driven tumors (basal cell carcinoma, medulloblastoma and atypical teratoid rhabdoid tumor) respond to JQ1 even when harboring genetic lesions rendering them resistant to Smoothened antagonists. Altogether, our results reveal BET proteins as critical regulators of Hedgehog pathway transcriptional output and nominate BET bromodomain inhibitors as a strategy for treating Hedgehog-driven tumors with emerged or a priori resistance to Smoothened antagonists.

Original languageEnglish (US)
Pages (from-to)732-740
Number of pages9
JournalNature medicine
Volume20
Issue number7
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Hedgehogs
Epigenomics
Tumors
Transcription
Medulloblastoma
Proteins
Chromatin
Genes
Neoplasms
Binding Sites
Cells
Chromatin Immunoprecipitation
Basal Cell Carcinoma
Protein C
Molecules
Carcinogenesis
Down-Regulation
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tang, Y., Gholamin, S., Schubert, S., Willardson, M. I., Lee, A., Bandopadhayay, P., ... Cho, Y-J. (2014). Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature medicine, 20(7), 732-740. https://doi.org/10.1038/nm.3613

Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. / Tang, Yujie; Gholamin, Sharareh; Schubert, Simone; Willardson, Minde I.; Lee, Alex; Bandopadhayay, Pratiti; Bergthold, Guillame; Masoud, Sabran; Nguyen, Brian; Vue, Nujsaubnusi; Balansay, Brianna; Yu, Furong; Oh, Sekyung; Woo, Pamelyn; Chen, Spenser; Ponnuswami, Anitha; Monje, Michelle; Atwood, Scott X.; Whitson, Ramon J.; Mitra, Siddhartha; Cheshier, Samuel H.; Qi, Jun; Beroukhim, Rameen; Tang, Jean Y.; Wechsler-Reya, Rob; Oro, Anthony E.; Link, Brian A.; Bradner, James E.; Cho, Yoon-Jae.

In: Nature medicine, Vol. 20, No. 7, 01.01.2014, p. 732-740.

Research output: Contribution to journalArticle

Tang, Y, Gholamin, S, Schubert, S, Willardson, MI, Lee, A, Bandopadhayay, P, Bergthold, G, Masoud, S, Nguyen, B, Vue, N, Balansay, B, Yu, F, Oh, S, Woo, P, Chen, S, Ponnuswami, A, Monje, M, Atwood, SX, Whitson, RJ, Mitra, S, Cheshier, SH, Qi, J, Beroukhim, R, Tang, JY, Wechsler-Reya, R, Oro, AE, Link, BA, Bradner, JE & Cho, Y-J 2014, 'Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition', Nature medicine, vol. 20, no. 7, pp. 732-740. https://doi.org/10.1038/nm.3613
Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature medicine. 2014 Jan 1;20(7):732-740. https://doi.org/10.1038/nm.3613
Tang, Yujie ; Gholamin, Sharareh ; Schubert, Simone ; Willardson, Minde I. ; Lee, Alex ; Bandopadhayay, Pratiti ; Bergthold, Guillame ; Masoud, Sabran ; Nguyen, Brian ; Vue, Nujsaubnusi ; Balansay, Brianna ; Yu, Furong ; Oh, Sekyung ; Woo, Pamelyn ; Chen, Spenser ; Ponnuswami, Anitha ; Monje, Michelle ; Atwood, Scott X. ; Whitson, Ramon J. ; Mitra, Siddhartha ; Cheshier, Samuel H. ; Qi, Jun ; Beroukhim, Rameen ; Tang, Jean Y. ; Wechsler-Reya, Rob ; Oro, Anthony E. ; Link, Brian A. ; Bradner, James E. ; Cho, Yoon-Jae. / Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. In: Nature medicine. 2014 ; Vol. 20, No. 7. pp. 732-740.
@article{0c4c3072eeed41fd8880112ba3e2f0e3,
title = "Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition",
abstract = "Hedgehog signaling drives oncogenesis in several cancers, and strategies targeting this pathway have been developed, most notably through inhibition of Smoothened (SMO). However, resistance to Smoothened inhibitors occurs by genetic changes of Smoothened or other downstream Hedgehog components. Here we overcome these resistance mechanisms by modulating GLI transcription through inhibition of bromo and extra C-terminal (BET) bromodomain proteins. We show that BRD4 and other BET bromodomain proteins regulate GLI transcription downstream of SMO and suppressor of fused (SUFU), and chromatin immunoprecipitation studies reveal that BRD4 directly occupies GLI1 and GLI2 promoters, with a substantial decrease in engagement of these sites after treatment with JQ1, a small-molecule inhibitor targeting BRD4. Globally, genes associated with medulloblastoma- specific GLI1 binding sites are downregulated in response to JQ1 treatment, supporting direct regulation of GLI activity by BRD4. Notably, patient- and GEMM (genetically engineered mouse model)-derived Hedgehog-driven tumors (basal cell carcinoma, medulloblastoma and atypical teratoid rhabdoid tumor) respond to JQ1 even when harboring genetic lesions rendering them resistant to Smoothened antagonists. Altogether, our results reveal BET proteins as critical regulators of Hedgehog pathway transcriptional output and nominate BET bromodomain inhibitors as a strategy for treating Hedgehog-driven tumors with emerged or a priori resistance to Smoothened antagonists.",
author = "Yujie Tang and Sharareh Gholamin and Simone Schubert and Willardson, {Minde I.} and Alex Lee and Pratiti Bandopadhayay and Guillame Bergthold and Sabran Masoud and Brian Nguyen and Nujsaubnusi Vue and Brianna Balansay and Furong Yu and Sekyung Oh and Pamelyn Woo and Spenser Chen and Anitha Ponnuswami and Michelle Monje and Atwood, {Scott X.} and Whitson, {Ramon J.} and Siddhartha Mitra and Cheshier, {Samuel H.} and Jun Qi and Rameen Beroukhim and Tang, {Jean Y.} and Rob Wechsler-Reya and Oro, {Anthony E.} and Link, {Brian A.} and Bradner, {James E.} and Yoon-Jae Cho",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/nm.3613",
language = "English (US)",
volume = "20",
pages = "732--740",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition

AU - Tang, Yujie

AU - Gholamin, Sharareh

AU - Schubert, Simone

AU - Willardson, Minde I.

AU - Lee, Alex

AU - Bandopadhayay, Pratiti

AU - Bergthold, Guillame

AU - Masoud, Sabran

AU - Nguyen, Brian

AU - Vue, Nujsaubnusi

AU - Balansay, Brianna

AU - Yu, Furong

AU - Oh, Sekyung

AU - Woo, Pamelyn

AU - Chen, Spenser

AU - Ponnuswami, Anitha

AU - Monje, Michelle

AU - Atwood, Scott X.

AU - Whitson, Ramon J.

AU - Mitra, Siddhartha

AU - Cheshier, Samuel H.

AU - Qi, Jun

AU - Beroukhim, Rameen

AU - Tang, Jean Y.

AU - Wechsler-Reya, Rob

AU - Oro, Anthony E.

AU - Link, Brian A.

AU - Bradner, James E.

AU - Cho, Yoon-Jae

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hedgehog signaling drives oncogenesis in several cancers, and strategies targeting this pathway have been developed, most notably through inhibition of Smoothened (SMO). However, resistance to Smoothened inhibitors occurs by genetic changes of Smoothened or other downstream Hedgehog components. Here we overcome these resistance mechanisms by modulating GLI transcription through inhibition of bromo and extra C-terminal (BET) bromodomain proteins. We show that BRD4 and other BET bromodomain proteins regulate GLI transcription downstream of SMO and suppressor of fused (SUFU), and chromatin immunoprecipitation studies reveal that BRD4 directly occupies GLI1 and GLI2 promoters, with a substantial decrease in engagement of these sites after treatment with JQ1, a small-molecule inhibitor targeting BRD4. Globally, genes associated with medulloblastoma- specific GLI1 binding sites are downregulated in response to JQ1 treatment, supporting direct regulation of GLI activity by BRD4. Notably, patient- and GEMM (genetically engineered mouse model)-derived Hedgehog-driven tumors (basal cell carcinoma, medulloblastoma and atypical teratoid rhabdoid tumor) respond to JQ1 even when harboring genetic lesions rendering them resistant to Smoothened antagonists. Altogether, our results reveal BET proteins as critical regulators of Hedgehog pathway transcriptional output and nominate BET bromodomain inhibitors as a strategy for treating Hedgehog-driven tumors with emerged or a priori resistance to Smoothened antagonists.

AB - Hedgehog signaling drives oncogenesis in several cancers, and strategies targeting this pathway have been developed, most notably through inhibition of Smoothened (SMO). However, resistance to Smoothened inhibitors occurs by genetic changes of Smoothened or other downstream Hedgehog components. Here we overcome these resistance mechanisms by modulating GLI transcription through inhibition of bromo and extra C-terminal (BET) bromodomain proteins. We show that BRD4 and other BET bromodomain proteins regulate GLI transcription downstream of SMO and suppressor of fused (SUFU), and chromatin immunoprecipitation studies reveal that BRD4 directly occupies GLI1 and GLI2 promoters, with a substantial decrease in engagement of these sites after treatment with JQ1, a small-molecule inhibitor targeting BRD4. Globally, genes associated with medulloblastoma- specific GLI1 binding sites are downregulated in response to JQ1 treatment, supporting direct regulation of GLI activity by BRD4. Notably, patient- and GEMM (genetically engineered mouse model)-derived Hedgehog-driven tumors (basal cell carcinoma, medulloblastoma and atypical teratoid rhabdoid tumor) respond to JQ1 even when harboring genetic lesions rendering them resistant to Smoothened antagonists. Altogether, our results reveal BET proteins as critical regulators of Hedgehog pathway transcriptional output and nominate BET bromodomain inhibitors as a strategy for treating Hedgehog-driven tumors with emerged or a priori resistance to Smoothened antagonists.

UR - http://www.scopus.com/inward/record.url?scp=84904036266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904036266&partnerID=8YFLogxK

U2 - 10.1038/nm.3613

DO - 10.1038/nm.3613

M3 - Article

VL - 20

SP - 732

EP - 740

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 7

ER -